Naveris to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference

Naveris Announces Expanded Medicare Coverage for the NavDx® Test in Identification of Molecular Residual Disease of Anal Squamous Cell Carcinoma

Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance

Naveris Announces Expanded Commercial Payor Coverage for NavDx Test from Blue Shield of California

Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting

Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting

New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings

Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting

Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer

Naveris Awarded ADLT Status by CMS for the NavDx® Test

Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024

Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to Advance HPV-Driven Cancer Diagnosis and Treatment

Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024

Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.

Naveris Receives Medicare Coverage for NavDx® Test

Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice

Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings

Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial

Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers

Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx

Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting

Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session

New Saliva Test Detects Head and Neck Cancer

Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers

Blood Test Accurately Identifies HPV-related Head and Neck Cancer Recurrence; Prospective Clinical Study Published in Journal of Clinical Oncology

Naveris Congratulates Scientific Advisors Bhisham Chera and Gaorav Gupta on Presentation of Clinical Data at the 2018 ASTRO Annual Meeting